MT4-MMP expression in breast adenocarcinoma stimulates tumor growth and metastatic spreading to the lung. However whether these pro-tumorigenic and pro-metastatic effects of MT4-MMP are related to a proteolytic action is not known yet. Through site directed mutagenesis MT4-MMP has been inactivated in cancer cells through Glutamic acid 249 substitution by Alanine in the active site. Active MT4-MMP triggered an angiogenic switch at day 7 after tumor implantation and drastically accelerated subcutaneous tumor growth as well as lung colonization in RAG -/-mice. All these effects were abrogated upon MT4-MMP inactivation. In sharp contrast to most MMPs being primarily of stromal origin, we provide evidence that tumor-derived MT4-MMP, but not host-derived MT4-MMP contributes to angiogenesis. A genetic approach using MT4-MMP-deficient mice revealed that the status of MT4-MMP produced by host cells did not affect the angiogenic response. Despite of this tumor intrinsic feature, to exert its tumor promoting effect, MT4-MMP requires a permissive microenvironment. Indeed, tumor-derived MT4-MMP failed to circumvent the lack of an host angio-promoting factor such as plasminogen activator inhibitor (PAI-1). Overall, our study demonstrates the key contribution of MT4-MMP catalytic activity in the tumor compartment, at the interface with host cells. It identifies MT4-MMP as a key intrinsic tumor cell determinant that contributes to the elaboration of a permissive microenvironment for metastatic dissemination.
Introduction
Tumor growth and metastatic dissemination are associated with an important tissue remodeling that requires different proteases. Matrix metalloproteases (MMPs) are zincdependent endopeptidases involved in physiological and pathological extracellular matrix remodeling and in cell function regulation 1 . Their roles in tumor growth, angiogenesis and metastasis are now well documented 1 . This protease family includes secreted/soluble (MMP) or membrane type-MMPs (MT-MMP) that are anchored to the cell surface through transmembrane domain or glycosylphosphatidylinositol (GPI) linker 2 . The most studied cell surface-associated MMP is MT1-MMP that has been originally identified as an MMP2 activator 3 , that regulates different cell functions including the glycolytic activity of tumor cells. It can also directly induce intracellular responses by controlling signal transduction through interaction with cell surface receptors 4 . The MT1-MMP driven intracellular signaling regulation seems to be, dependent or independent on its catalytic functions. In this context, it is worth mentioning that MT1-MMP participates in ERK1/2 pathway activation during cell migration in a non-catalytic manner after TIMP-2 binding [5] [6] [7] .
Membrane-type 4 MMP (MT4-MMP, also known as MMP-17) is a member of the GPI-anchored MT-MMP subgroup that is structurally and functionally distant from other MTMMPs. MT4-MMP was originally cloned form a human carcinoma cDNA library 8, 9 and its mRNA expression was detected in brain, spleen, uterus, ovary and leukocytes in both human and mousse tissues [9] [10] [11] [12] [13] [14] . Recently, several reports have provided information on MT4-MMP function in physiological conditions. MT4-MMP deficient mice develop normal and show no abnormalities compared to wild-type mice 14 , suggesting that MT4-MMP is not requested for normal development in survival. However, a recent study reported that Mt4-mmp-/-mice have abnormal diminished thirst that could be a result of dysfunction in thirst regulation in the brain 15 . MT4-MMP seems to contribute to the control of cartilage aggrecan integrity in vitro and in vivo by its capacity to activate ADAMTS-4 through C-terminal domain processing 16 .
The ability of MT4-MMP to form a complex with ADAMTS4 recently evidenced by coimmunoprecipitation further support this concept 17 . Accordingly, genetic deletion of MT4-MMP protects mice against IL-1β-induced loss of articular glycosaminoglycans, reinforcing the role of MT4-MMP in agreccan proteolysis in vivo 18 . On the focus of the present study is the role of MT4-MMP's catalytic activity in tumor progression.
Previously, we demonstrated that MT4-MMP is localized in cancer cells, but not in stromal compartment of human breast cancer 19 . MT4-MMP overexpression accelerates the in vivo growth and promotes the metastatic dissemination of breast cancer cells through tumor vessel architecture alteration 19, 20 . In line with these data, MT4-MMP plays a significant role in hypoxia-mediated metastasis and is also an important prognostic indicator in patients with head and neck cancer 21 . In comparison with the abundant information currently available on other MT-MMPs, MT4-MMP mechanisms of action in cancer remain to be established. In contrast to MT1-MMP, MT4-MMP does not cleave collagens, it is a poor pro-MMP2 activator and has a restricted substrate repertoire including pro-TNF-α, α2-macroglobulin 22 , low density lipoprotein receptor related protein (LRP) 23 and aggrecanase (ADAMTS-4) 18 .
Whether the pro-metastatic effect of MT4-MMP relies on its catalytic activity is still not yet known. In this report, we addressed this important issue by evaluating the effect of overexpression of MT4-MMP catalytically-inactive mutant, on in vitro and in vivo angiogenesis, tumor growth and lung metastases. We investigated MT4-MMP functions in physiological and pathological angiogenesis in a non permissive environment. We provide evidence that MT4-MMP triggers angiogenic switch through its catalytic activity in a permissive host environment favorable for tumor progression.
Materials and methods

Cell Culture
Human breast cancer MDA-MB-231 cells were obtained from the American Type Culture Collection (Manassas, VA) and HEK-293T cells were purchased from Thermo Scientific-Open Biosystems (Wilmington, DE). Cells were grown as described previously 19 .
Inactivation of the MT4-MMP and cell transfection
Inert MT4-MMP was produced by site-directed mutagenesis in the highly conserved domain HExxHxxGxxH through point mutation of Glutamic acid at position 249 with Glu249
with Alanin 24-26 . The primers used to introduce the mutation were designed as follows: 6 monolayer using High Pure RNA isolation kit (Roche) or from tumor tissue using High Pure RNA tissue kit (Roche Diagnostic Applied Science, Mannheim, Germany).
RT-PCR analysis
RT-PCR was performed as described previously 19 . Specific primers for MT4-MMP 
Western blot analysis
Samples were separated as described previously 19 . 
Cell surface biotinylation
MDA-MB231 cells stably expressing wild type (MT4) or inactive MT4-MMP (MT4-E249A) were incubated 100 mm dish and cell surface biotinylated with the cell impermeable
EZlink-sulfo-NHS-biotin (Pierce) as described previously 6 . The cells were then lysed with 0.5 ml/well of cold lysis buffer on ice. After centrifugation, 500 µg of total protein were incubated with streptavidin-agarose beads (Sigma) overnight at 4°C. The precipitated samples were analyzed by western blotting with the MT4-MMP and MT1-MMP antibodies.
Immunofluorescence
Cells were incubated on cover slip in 24-well culture plate at 5x10 Vector Laboratories, Burlingame, CA, USA). Fluorescence microscopy analysis was realized using 40-fold magnification.
Flow cytometry
Cells were detached with PBS/EDTA 2.5 mM, counted and 5x10 5 
In vitro BrdU proliferation assay
In vitro proliferation growth rate was assessed using BrdU kit (11647229001; Roche 29 . Tumor growth was assessed as described previously 19 .
Immunohistochemistry
Slides were autoclaved for 11 min at 126°C in Target For quantitative measurement of human Ki-67 staining related to human vimentin staining, a specific automatic computer-assisted image analysis was applied on sections by using Application Software (3.2). In RGB images, human vimentin appeared in red and Ki-67 in brown colors. After separation of those components, red and brown images were binarized automatically and these binarized images were used to determine the colocalization of vimentin and ki-67 using a logical operator (AND). The colocalization area density for each condition was finally determined.
Matrigel plug assays
Mt4-mmp-/-mice (previously generated by Motoharu Seiki's laboratory, University of Tokyo, Japan) 14 were subjected to matrigel plug assay. Matrigel (500 µl) supplemented with 
Aortic ring assay
Aortic explants from Mt4-mmp -/-mice (n=6) or Mt4-mmp +/+ mice (n=6) were incubated for 6 days at 37°C according to the procedure previously described 30 . Images were captured on Zeiss microscope at day 6. A total number of 18 explants were tested by using three aortic explants of each mouse. Computerized quantification of vessel density and branching was performed as previously described 31 .
Corneal whole mounts
Corneal lymphangiogenesis was assessed in Mt4-mmp -/-(n=6; number of cornea=12)
and Mt4-mmp +/+ mice (n=6; number of cornea=12) induced by thermal cauterization of the central cornea with an ophthalmic cautery (OPTEMP II V, Alcon Surgical, FortWorth, USA).
Seven days after cauterization, corneas were resected and blood vessels were highlighted after over-night incubation with rat anti-mouse CD31 monoclonal antibody (Pharmingen, 01951D).
Corneas were washed with PBS and incubated 2 hours incubation at room temperature with Alexa Fluor 488 conjugated rabbit anti-goat antibody (Molecular Probes). Computerized quantification of vessel density was performed according to Blacher et al. 32 . Results are expressed as normalized vessel density (Ni) plotted as function of the distance from the external border of the cornea.
Statistical analysis
We assessed statistical differences between different experimental groups using MannWhitney test. P-value < 0.05 (*) was considered as significant. Statistical analyses were carried out using the Prism 4.0 software (GraphPad, San Diego, CA). * = p < 0.05; ** = p < 0.01.
Results
The inactivation of MT4-MMP activity does not influence its shedding from the cell surface
To test the importance of the MT4-MMP catalytic activity on cell based system in vitro and on tumor malignancy in vivo, we have generated a mutated inactive form of the enzyme. Using a similar approach previously described to generate inactive MT1-MMP (MT1-E240A) 33 , the highly conserved Glutamic acid-249 ( To assess cell surface-associated MT4-MMP, cells were surface biotinylated. Biotinlabeled proteins, including MT4-MMP, were precipitated using streptavidin-agarose beads.
The levels of MT4-MMP in the precipitates were determined by Western blotting ( Figure   1D ). MT4-MMP was not detected in control cells. In cells over-expressing MT4-MMP, the amount of membrane-associated MT4-MMP was significantly higher for the intact than for the mutated MT4-E249A form. These data are in line with those obtained with total cell lysates and through flow cytometry analysis. Since mRNA levels were similar in all cell types, differences at protein levels on the cell surface could rely on posttranslational regulation such as for instances protein shedding or internalization. We checked that MT1- There is a large body of evidences demonstrating that PAI-1 is an important host determinant regulating the angiogenic switch in early steps of cancer progression 35 
MT4-MMP is a selective tumor cell determinant of cancer progression
We next wonder whether MT4-MMP produced by host cells could also affect Similarly, identical angiogenesis was evidenced in the matrigel plug assay applied to mutant and WT mice ( Figure 5C ). These data suggest that MT4-MMP expression by host cells did not affect angiogenesis in vivo. We next extended our exploration to angiogenic process associated with tissue injury repair. In the corneal assay induced by thermal cauterization, blood vessels sprouting from the limb and migrating into the cornea center were visualized by immunostaining of whole mounted cornea with an anti CD31 antibody ( Figure 5D ). Similar decrease of vessel density from corneal periphery to the center of lesion was seen in the two mice genotypes ( Figure 5E ). All together, these data demonstrate that MT4-MMP expression in host cells did not affect angiogenesis.
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Discussion
Although MT4-MMP has been shown to induce tumor growth and metastasis, the extent to which the effect is mediated through its proteolytic activity has not been examined yet. In this study, we evaluated the pro-angiogenic, the pro-metastatic and pro-tumorigenic effects of active site defective MT4-MMP mutant. We first generated stable adenocacinoma cells expressing the inactive form of MT4-MMP and characterized its production, processing and shedding in vitro. The shedding of MT4-MMP from cell surface was not inhibited by inactivating mutation of the enzyme, demonstrating that MT4-MMP did not shed itself from cell surface. However, the form shed in the conditioned media was cleaved and generated a angiogenic host determinant such as PAI-1. It was worth addressing this issue since our previous work demonstrated that the angiogenic effect of PAI-1 on human cervical and skin carcinoma cells was dependent to their intrinsic invasive potential 29 . Indeed, the lack of PAI-1 significantly reduced the incidence of subcutaneous tumors derived from poorly aggressive
HaCaT II-4 cells, but not the incidence of tumors derived from the more aggressive HaCaT A5-RT3 cells 29 . 46 . The concept that cancer cell-specific proteinase contributes to angiogenesis within the tumor stroma is supported by a study reporting the capacity of MMP7 to cleave connective tissue growth factor (CTGF), a VEGF sequester 47 . MT4-MMP is among the very few MMPs selectively produced in the tumor compartment, as demonstrated in human breast cancer samples 19 . To determine whether host-derived MT4-MMP could contribute to angiogenesis, we applied to Mt4-mmp-/-mice three powerful models of angiogenesis: the aortic ring assay, the matrigel plus assay and, the corneal assay 32, 39, 48 . Our data show that MT4-MMP expression in host cells did not affect angiogenesis in none of these models. This 
